Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ekkehard Eigendorff

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)|September 11, 2018
[Chronic Myelogenous Leukemia]Andreas Hochhaus, Ekkehard Eigendorff, Thomas Ernst
Annals of Hematology|March 28, 2015
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patientsAndreas Hochhaus, Thomas Ernst, Ekkehard Eigendorff, et al.
Journal of Cancer Research and Clinical Oncology|December 30, 2015
Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds?Mehmet Metin Yildiz, Iver Petersen, Ekkehard Eigendorff, et al.
Journal of Cancer Research and Clinical Oncology|May 24, 2017
Surgery for colorectal cancer in elderly patients: how can we improve outcome?Henning Mothes, Astrid Bauschke, Silke Schuele, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoidsSven Diederich, Ekkehard Eigendorff, Patrick Burkhardt, et al.
Cancer Medicine|October 12, 2016
Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, GermanyIrene Göllnitz, Johanna Inhestern, Thomas G Wendt, et al.
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
The New England Journal of Medicine|June 5, 2023
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung CancerHeather Wakelee, Moishe Liberman, Terufumi Kato, et al.
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Deutsche Medizinische Wochenschrift (1946)|September 11, 2018
[Chronic Myelogenous Leukemia]Andreas Hochhaus, Ekkehard Eigendorff, Thomas Ernst
Annals of Hematology|March 28, 2015
Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patientsAndreas Hochhaus, Thomas Ernst, Ekkehard Eigendorff, et al.
Journal of Cancer Research and Clinical Oncology|December 30, 2015
Which is the most suitable lymph node predictor for overall survival after primary surgery of head and neck cancer: pN, the number or the ratio of positive lymph nodes, or log odds?Mehmet Metin Yildiz, Iver Petersen, Ekkehard Eigendorff, et al.
Journal of Cancer Research and Clinical Oncology|May 24, 2017
Surgery for colorectal cancer in elderly patients: how can we improve outcome?Henning Mothes, Astrid Bauschke, Silke Schuele, et al.
The Journal of Clinical Endocrinology and Metabolism|December 6, 2002
11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoidsSven Diederich, Ekkehard Eigendorff, Patrick Burkhardt, et al.
Cancer Medicine|October 12, 2016
Role of comorbidity on outcome of head and neck cancer: a population-based study in Thuringia, GermanyIrene Göllnitz, Johanna Inhestern, Thomas G Wendt, et al.
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
The New England Journal of Medicine|June 5, 2023
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung CancerHeather Wakelee, Moishe Liberman, Terufumi Kato, et al.
Journal of the National Cancer Institute|March 6, 2016
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United StatesWilliam V Padula, Richard A Larson, Stacie B Dusetzina, et al.
Lancet (London, England)|September 17, 2024
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialJonathan D Spicer, Marina C Garassino, Heather Wakelee, et al.
Pageof 1